2cureX appoints Mangold Fondkommission AB as new Certified Adviser
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-26 | 13:00 | Bokslutskommuniké 2025 |
| 2025-08-21 | 13:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-27 | N/A | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2025-06-26 | N/A | Årsstämma |
| 2025-02-27 | - | Bokslutskommuniké 2024 |
| 2024-12-18 | - | Extra Bolagsstämma 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-11-14 | - | Extra Bolagsstämma 2023 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-29 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-26 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2023-02-10 | - | Extra Bolagsstämma 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-25 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-02 | - | Extra Bolagsstämma 2020 |
| 2020-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-05-28 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2019-05-28 | - | Årsstämma |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-02 | - | Extra Bolagsstämma 2019 |
| 2019-03-01 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-29 | - | X-dag ordinarie utdelning 2CUREX 0.00 SEK |
| 2018-05-28 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2cureX AB has entered into an agreement with Mangold Fondkommission AB (“Mangold”) regarding the service as Certified Adviser.
Mangold will take over as Certified Adviser on 26 May 2025. Until then, Redeye AB will continue to hold the assignment as Certified Adviser for the company.
For more information about 2cureX:
Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346
Kenneth Graabek Johansen, Chief Financial Officer
E-mail: KGJ@2curex.com
Telephone: +45 23 49 02 27
About 2cureX
2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
• IndiTreat® Start (first-line therapy)
• IndiTreat® Extend & Explore (third-line options)
New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.
2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.